Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

Kenneth W. Mahaffey,Meg Jardine,Meg Jardine,Severine Bompoint,Christopher P. Cannon,Bruce Neal,Bruce Neal,Bruce Neal,Hiddo J. Lambers Heerspink,Hiddo J. Lambers-Heerspink,David M. Charytan,Robert Edwards,Rajiv Agarwal,George L. Bakris,Scott Bull,George Capuano,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,Tao Sun,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Norman Rosenthal,Barry M. Brenner,Vlado Perkovic,Vlado Perkovic

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial

2019

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effec...

Keywords:

Internal medicine
Kidney
Diabetes mellitus
Kidney disease
Cardiology
Canagliflozin
Type 2 diabetes
Medicine

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations